ATE550074T1 - Fumarat aus 4-((4-((4-(2-cyanoethenyl)-2,6- dimethylphenyl amino -2-pyrimidinyl amino benzonitril - Google Patents

Fumarat aus 4-((4-((4-(2-cyanoethenyl)-2,6- dimethylphenyl amino -2-pyrimidinyl amino benzonitril

Info

Publication number
ATE550074T1
ATE550074T1 AT05779369T AT05779369T ATE550074T1 AT E550074 T1 ATE550074 T1 AT E550074T1 AT 05779369 T AT05779369 T AT 05779369T AT 05779369 T AT05779369 T AT 05779369T AT E550074 T1 ATE550074 T1 AT E550074T1
Authority
AT
Austria
Prior art keywords
amino
cyanoethenyl
fumarate
pyrimidinyl
dimethylphenyl
Prior art date
Application number
AT05779369T
Other languages
English (en)
Inventor
Paul Theodoor Stevens
Jozef Peeters
Roger P Vandecruys
Alfred E Stappers
Alex Herman Copmans
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from MYPI20043578A external-priority patent/MY169670A/en
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Priority claimed from PCT/EP2005/054341 external-priority patent/WO2006024667A1/en
Application granted granted Critical
Publication of ATE550074T1 publication Critical patent/ATE550074T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • AIDS & HIV (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT05779369T 2004-09-02 2005-09-02 Fumarat aus 4-((4-((4-(2-cyanoethenyl)-2,6- dimethylphenyl amino -2-pyrimidinyl amino benzonitril ATE550074T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
MYPI20043578A MY169670A (en) 2003-09-03 2004-09-02 Combinations of a pyrimidine containing nnrti with rt inhibitors
PCT/EP2004/052028 WO2005021001A1 (en) 2003-09-03 2004-09-03 Combinations of a pyrimidine containing nnrti with rt inhibitors
EP05101447 2005-02-25
PCT/EP2005/054341 WO2006024667A1 (en) 2004-09-02 2005-09-02 Furamate of 4-( (4-( (4- (2-cyanoethenyl) -2,6-dimethylphenyl)amino)-2-pyrimidinyl)amino)benzonitrile

Publications (1)

Publication Number Publication Date
ATE550074T1 true ATE550074T1 (de) 2012-04-15

Family

ID=38091631

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05779369T ATE550074T1 (de) 2004-09-02 2005-09-02 Fumarat aus 4-((4-((4-(2-cyanoethenyl)-2,6- dimethylphenyl amino -2-pyrimidinyl amino benzonitril

Country Status (19)

Country Link
US (3) US20090215804A1 (de)
EP (1) EP1789139B1 (de)
JP (1) JP4922937B2 (de)
KR (1) KR101276571B1 (de)
AP (1) AP2487A (de)
AT (1) ATE550074T1 (de)
AU (1) AU2005279157B2 (de)
BR (1) BRPI0514861A (de)
CA (1) CA2577273C (de)
CR (1) CR9032A (de)
DK (1) DK1789139T3 (de)
EA (1) EA011036B1 (de)
ES (1) ES2384715T3 (de)
HR (1) HRP20120499T1 (de)
IL (1) IL181649A0 (de)
MX (1) MX2007002594A (de)
NI (1) NI200700069A (de)
NO (1) NO339788B1 (de)
SI (1) SI1789139T1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9126949B2 (en) 2011-04-25 2015-09-08 Hetero Research Foundation Process for rilpivirine
US20210128466A1 (en) * 2019-10-10 2021-05-06 Axcella Health Inc. Reduced volume formulations including amino acid entities

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5498419A (en) * 1994-06-03 1996-03-12 Pars; Harry G. Fumarate salt of 4-(diethyl-3-(1-methyloctyl)-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-dibenzo[b,d]pyran-1-ol, 4-(diethyl-amino) butyric
WO1998029095A2 (en) * 1997-01-03 1998-07-09 Elan Corporation, Plc Sustained release cisapride mini-tablet formulation
MY169670A (en) * 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
JO3429B1 (ar) * 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
US7399856B2 (en) * 2002-08-09 2008-07-15 Janssen Pharmaceutica N.V. Processes for the preparation of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-2pyrimidinyl]amino]benzonitrile
AU2002350719A1 (en) * 2002-11-29 2004-06-23 Janssen Pharmaceutica N.V. Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
EP1597237B1 (de) * 2003-02-07 2016-07-27 Janssen Pharmaceutica NV Pyrimidinderivate zur Prävention von HIV-Infektion
WO2004071374A2 (en) * 2003-02-11 2004-08-26 Torrent Pharmaceuticals Limited Once a day orally administered pharmaceutical compositions

Also Published As

Publication number Publication date
AP2487A (en) 2012-10-03
CR9032A (es) 2009-07-30
US20180116964A1 (en) 2018-05-03
US20090215804A1 (en) 2009-08-27
SI1789139T1 (sl) 2012-08-31
KR20070053284A (ko) 2007-05-23
IL181649A0 (en) 2007-07-04
AU2005279157B2 (en) 2011-07-14
NO339788B1 (no) 2017-01-30
EA011036B1 (ru) 2008-12-30
EP1789139B1 (de) 2012-03-21
CA2577273C (en) 2013-11-19
US20110150996A1 (en) 2011-06-23
EA200700534A1 (ru) 2007-08-31
ES2384715T3 (es) 2012-07-11
JP4922937B2 (ja) 2012-04-25
MX2007002594A (es) 2007-04-25
JP2008511591A (ja) 2008-04-17
CA2577273A1 (en) 2006-03-09
NO20071720L (no) 2007-04-02
DK1789139T3 (da) 2012-07-09
KR101276571B1 (ko) 2013-06-18
AU2005279157A1 (en) 2006-03-09
HRP20120499T1 (hr) 2012-07-31
AP2007003933A0 (en) 2007-04-30
EP1789139A1 (de) 2007-05-30
HK1112862A1 (en) 2008-09-19
BRPI0514861A (pt) 2008-06-24
NI200700069A (es) 2015-12-10

Similar Documents

Publication Publication Date Title
HUS1600061I1 (hu) 4[[4-[[4-(2-cianoetenil)-2,6-dimetilfenil]-2-pirimidinil]amino]benzonitril
JO2973B1 (en) Fumarate salt for (alpha-beta-R) -6-bromo-alpha-[2- (methylamino) ethyl-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinoline ethanol
TW200633716A (en) Compositions and methods for stabilizing active pharmaceutical ingredients
MEP33808A (hr) Farmaceutske kompozicije koje obuhvataju inhibitor hmg reduktaze
MX338920B (es) Proceso para la preparacion de compuestos de aminocrotonilo.
JO2515B1 (en) Gamma-Crystalline form of ivabradine hydrochloride,a process for its preparation and pharmaceutical composition containing it
WO2009007441A3 (en) Crystalline form of (e) 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2 pyrimidinyl]amino]benzonitrile
DE602005014382D1 (de) 2-pyrimidinyl-pyrazolopyridin-erbb-kinaseinhibitoren
NO20050524L (no) Fremgangsmater for fremstillingen av 4-[[4-[[4-(2-cyanoetenyl)-2,6-dimetylfenyl]amino]-2-pyrimidinyl]amino]benzonitril
NO20042844L (no) 4-(piperidyl- og pyrrolidyl-alkyl-ureido)-kinoliner som uprotensin II reseptor-antagonister
TW200609001A (en) Particulate-stabilized injectable pharmaceutical compositions of posaconasole
ATE541573T1 (de) Pharmazeutische zusammensetzung enthaltend lapatinib
IL181649A0 (en) Furamate of 4-((4-((4-(2-cyanoethenyl)-2,6-dimethylphenyl)amino)-2-pyrimidinyl)amino) benzonitrile
UA92469C2 (en) Fumarate of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl amino benzonitrile
EA200801614A1 (ru) Фармацевтическая композиция, содержащая монтелукаст
HRP20110563T1 (en) Salt of 4[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
UY27049A1 (es) Composiciones farmacéuticas